Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck halts vorapaxar Phase III trial in ACS patients, amends TRA-2P Phase III trial

This article was originally published in Scrip

Executive Summary

Merck has announced major changes to two Phase III clinical studies of vorapaxar, an investigational cardiovascular focused therapeutic candidate that it acquired through the acquisition of Schering-Plough, following a review by a combined data safety and monitoring board. As a result of the safety and efficacy review, the company is discontinuing the TRACER study in patients with acute coronary syndrome (ACS) while the TRA-2P study, which is evaluating the compound in secondary prevention of heart attacks will only continue in a narrower patient population.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC011468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel